Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical
company focused on the discovery and development of biased ligands
targeting G protein coupled receptors, today announced that the
company will give two oral presentations at the 2016 Annual Meeting
of the American Society of Anesthesiologists being held at
McCormick Place in Chicago, Illinois, on October 22-26, 2016. Both
presentations will highlight Phase 2 data on oliceridine, Trevena’s
Breakthrough Therapy-designated lead product candidate being
developed as a first line intravenously-administered treatment for
patients experiencing moderate-to-severe acute pain.
In parallel to the conference, the company will be webcasting a
thought leader symposium that will discuss unmet needs associated
with current injectable analgesics and how oliceridine may fit into
the current treatment landscape for acute moderate to severe pain.
The webcast will begin at 5:00 p.m. EDT (4:00 p.m. CDT) on Monday,
October 24.
To access the live audio webcast of the thought leader
symposium, please visit the “Investors” section of the company’s
website at www.trevena.com. Following the conclusion of the
presentation, the webcast will be archived for 30 days.
The company also is sponsoring an accredited continuing medical
education (CME) symposium entitled “Gaining Insight into Emerging
Pain Management Therapies in an Acute Setting” that will review
current and new acute pain management therapies.
Details for the conference events are as follows:
Oral presentations
Title:
Rapid Onset of Pain Relief With Oliceridine (TRV130), a Novel
µ-GPS, Versus Morphine
Presenter:
Eugene R. Viscusi, M.D., Professor of Anesthesiology, Sidney Kimmel
Medical College at Thomas Jefferson University
Presentation number:
A5037
Presentation session:
OR16-1: Regional Anesthesia and Acute Pain, October 26, 2016, 9:45
– 11:15 a.m. CT
Title:
Duration of PCA Interruptions with Oliceridine (TRV130), a novel
µ-GPS, vs. Morphine
Presenter:
Jianguo Cheng, M.D., Ph.D, Professor of Anesthesiology, Case
Western Reserve University
Presentation number:
A5037
Presentations session:
OR16-1: Regional Anesthesia and Acute Pain, October 26, 2016, 9:45
– 11:15 a.m.
Thought leader symposium
Title:
Oliceridine and Unmet Needs in Injectable Analgesia
Presenters:
David Soergel, M.D., Chief Medical Officer, Trevena Keith
Candiotti, M.D., Professor of Anesthesiology and Internal Medicine,
University of Miami School of Medicine, Florida Timothy Beard,
M.D., FACS, Chair of Department of Surgery, Bend Memorial Clinic,
Oregon Eric Lavonas, M.D., FACEP, Professor of Emergency Medicine,
University of Colorado School of Medicine, Colorado; past Chair of
the Pharmacy & Therapeutics Committee, Denver Health and
Hospital Authority Carrie Bourdow, Chief Commercial Officer,
Trevena
Time:
5:00 – 7:00 p.m. EDT (4:00 – 6:00 p.m. CDT)
Accredited Satellite Symposium
Title:
Gaining Insight into Emerging Pain Management Therapies in an Acute
Setting
Time and location:
Hyatt Regency Chicago, Regency Ballroom CD, October 24, 2016, 6:00
– 8:00 a.m. CT
About Trevena
Trevena, Inc. is a clinical stage biopharmaceutical company that
discovers, develops, and intends to commercialize therapeutics that
use a novel approach to target G protein coupled receptors, or
GPCRs. Oliceridine (TRV130), Trevena’s lead product candidate, is
the first pain program granted Breakthrough Therapy designation by
the U.S. Food & Drug Administration and is in Phase 3
development for intravenous management of moderate to severe acute
pain. In Phase 2b, intravenous oliceridine demonstrated rapid and
powerful analgesic efficacy with fewer opioid-related adverse
events including nausea, vomiting, and respiratory events compared
to intravenous morphine, thus offering a promising safety and
tolerability profile compared to conventional opioid analgesics
while providing powerful pain relief to patients.
Cautionary Note on Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development of its
therapeutic candidates, plans for potential future product
candidates and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “suggest,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
status, timing, costs, results and interpretation of the Company’s
clinical trials; the uncertainties inherent in conducting clinical
trials; whether interim results from a clinical trial will be
predictive of the final results of the trial or results of early
clinical trials will be indicative of the results of future trials;
expectations for regulatory approvals; availability of funding
sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements;
uncertainties related to the Company’s intellectual property; other
matters that could affect the availability or commercial potential
of the Company’s therapeutic candidates, including how oliceridine
may fit into the current treatment landscape for acute moderate to
severe pain; and other factors discussed in the Risk Factors set
forth in the Company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission (SEC) and in other filings the Company makes with the
SEC from time to time. In addition, the forward-looking statements
included in this press release represent the Company’s views only
as of the date hereof. The Company anticipates that subsequent
events and developments may cause the Company’s views to change.
However, while the Company may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so, except as may be
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017006477/en/
Investor Contact:Trevena, Inc.Jonathan Violin, Ph.D.Sr.
director of investor relations610-354-8840
x231jviolin@trevena.comorMedia Contact:Trevena, Inc.Public
RelationsPR@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024